# US 2016/0237093 A1 · Therapeutic compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237093 A1
- Document ID: US20160237093A1
- Status: Published application
- Kind: A1
- Application number: 15/139,107
- Filed: 2016-04-26
- Published: 2016-08-18
- Earliest claimed: 2013-02-15
- Assignees: Kala Pharmaceuticals, Inc.
- Applicants: Kala Pharmaceuticals, Inc.
- Inventors: Winston Zapanta Ong; Pawel Wojciech Nowak; Ben C. Askew; Jinsoo Kim
- Web page: https://patentgrep.com/patent/US20160237093A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/88: Oxygen atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is H or C1-6 alkyl;
R2 is heterocyclyl;
X is a bond, —O—, or —C(═O)—;
each instance of R3 is independently H, F, Cl, Br, I, CN, or OH;
Z is optionally substituted aliphatic, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted quinolyl;
m is 0, 1, 2, 3, or 4; and
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 2 (depends on 1)

The compound of claim 1, wherein m is 0.

### Claim 3 (depends on 1)

The compound of claim 1, wherein m is 1 and R3 is CI.

### Claim 4 (depends on 1)

The compound of claim 1, wherein m is 1 and R3 is F.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein R, is CH3.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is optionally substituted isooxazolyl.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is optionally substituted phenyl.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is:
wherein e, f, and h are independently 1, 2, or 3.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is C1-6 alkyl.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein Z is optionally substituted thiophenyl.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein X is a bond.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein X is —O—.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein X is —C(═O)—.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein n is 1.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein n is 2.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein R2 is:
wherein p and q are independently 0, 1, 2, 3, or 4.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein R2 is:
wherein p, q, s, and t are independently 0, 1, 2, 3, or 4.

### Claim 18 (depends on 1)

The compound of claim 1, which is:

### Claim 19 (depends on 1)

A method of treating an ocular disease comprising administering a compound according to claim 1 to a subject in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the ocular disease is a retinopathy, age-related macular degeneration, or glaucoma.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is suitable for administration to an eye.

### Claim 23

A compound of Formula (VI):
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is H or optionally substituted C1-6 alkyl;
R2 is heterocyclyl;
X is a bond, —O—, or —C(═O)—;
each instance of R3 is independently H, F, Cl, Br, I, CN, or OH;
Y is CH;
Z is optionally substituted aliphatic, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted quinolyl;
m is independently 0, 1, 2, 3, or 4; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 24 (depends on 23)

A method of treating an ocular disease comprising administering a compound according to claim 23 to a subject in need thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the ocular disease is a retinopathy, age-related macular degeneration, or glaucoma.

### Claim 26 (depends on 23)

A pharmaceutical composition comprising a compound of claim 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
